A cationic lipid-based gene delivery system composed of N- [(1-(2,3-dioleyloxy)propyl)]-N-N-N-trimethylammonium chloride and cholesterol, at a 4:1 molar ratio, was developed for systemic administration. Plasmid biodistribution and expression were characterized in syngeneic mouse tumor model squamous cell carcinoma VII cells. A reporter gene expression plasmid was used for biodistribution of plasmid and expression. The results showed that lungs and primary tumors were transfected. Fluorescence microscopy showed that fluorescent-labeled transfection complexes were passively targeted to the tumor vasculature and that the endothelial cells internalized the plasmid. Transgene expression was characterized based on duration of expression and dosing schedule. In vivo gene transfer with an interleukin-12 expression plasmid yielded protein levels in blood, lungs, and primary tumor after intravenous administration. Efficacy studies showed that 15 g of interleukin-12 plasmid was sufficient to produce a gene-specific inhibition of primary tumor growth. These results characterize the vascularity of the tumor model, characterize the in vivo gene transfer properties of the plasmid-based gene delivery system, and show that the transgene expression level was sufficient to elicit a biological response by inhibiting tumor growth.
S ystemic administration of cationic lipid/plasmid transfection complexes yields predominant transfection of the lungs, with the major transfected cell type being the endothelium. [1] [2] [3] This mode of gene delivery has been applied to the treatment of lung cancer. Expression of genes that impact tumor growth, such as tumor suppressor protein p53 or the antiangiogenic factor angiostatin, 4 were shown to be effective in inhibiting the development of metastatic lesions. Treatment of cancers other than lung metastases may require an alternate strategy due to the predominant delivery to the lungs. One approach has been to use intramuscular administration of plasmids encoding antiangiogenic factors, thus converting the muscle into a bioreactor for production of secreted gene product into the bloodstream. Expression of endostatin, an antiangiogenic factor, from muscle was shown to suppress both primary tumor growth and metastatic lesion development in the lung. 5 In another study, interleukin-12 (IL-12) was expressed after intramuscular plasmid administration and was shown to inhibit the formation of lung metastatic lesions with no significant impact on pre-existing tumors. 6 We have recently characterized a lipid-based gene delivery system for transfection of primary subcutaneous (s.c.) tumors after intravenous (i.v.) administration. 7 In the present report, the pharmacological characteristics of the transfection complexes are described. These include measuring plasmid uptake and expression in tumor and lungs, demonstration of plasmid uptake by tumor endothelium, and extended expression from tumors after repeat administration. The biological activity of expressed therapeutic proteins after systemic administration was demonstrated in a mouse tumor model by inhibiting the growth rate of primary tumors.
MATERIALS AND METHODS

Animal models of tumor angiogenesis
Subcutaneous solid tumors were created in 6-to 8-week-old female C3H mice (20 -22 g ) (Charles River Laboratories, Raleigh, NC) by s.c. injection of 4 ϫ 10 5 squamous cell carcinoma VII (SCCVII) cells. 8 Tumor size before and after treatment with formulated plasmid was measured with a micrometer caliper. Tumor volume was calculated from the length, width, and height of the tumor.
Assays for tumor vascularity
Tumor vascularity was determined by i.v. administration of 100 L of 5% fluorescein isothiocyanate (FITC)-labeled dextran sulfate (Sigma, St. Louis, Mo) in 5% glucose in tumor-bearing mice. At 5 minutes after dextran injection, tumors were harvested, embedded in OCT embedding medium (Sakura Finetek, Torrance, Calif) in cryomolds, and quickly frozen by immersion in chilled isopentane. Tissue cryosections (5 m)
were examined with an Olympus BX-60 fluorescence microscope (Melville, NY) and photographed with a Montague spot camera (Diagnostic Instruments, Michigan, Ill). The amount of tissue-bound fluorescent dextran was measured spectrophotometrically. Briefly, the tissue was homogenized in 1 mL of TENT buffer (10 mM tris(hydroxymethyl)aminomethane (Tris), 1 mM ethylenediaminetetraacetic acid (EDTA), 0.1 M NaCl, and 0.5% Triton X-100) and centrifuged at 10,000 ϫ g for 15 minutes. FITC-dextran fluorescence was measured at 494/520-nm excitation/emission with an LS50B fluorescence spectrometer (Perkin-Elmer, Buckinghamshire, UK).
CD31 and bromodeoxyuridine (BrdU) immunostaining of tumor endothelial cells
Tumor paraffin cryosections (5 m; JUNG CM3000) were first incubated with a rat anti-mouse CD31 antibody (Ab) and subsequently with a rabbit anti-rat immunoglobulin G labeled with Texas Red fluorophore. The tumor sections were fixed in formaldehyde and counterstained with Vectashield (Vector Laboratories, Burlingame, CA) mounting medium containing 4Ј,6-diamidino-2-phenylindole. Anti-CD31 and anti-BrdU immunostaining of enzymatically dispersed tumors was performed as follows. Excised tumors were minced, resuspended in buffer (75 g of type I collagenase/mL, 50 g of deoxyribonuclease I/mL in Hanks' balanced salt solution), and shaken with zirconium beads for 90 minutes at 37°C. The digested tissue was filtered through a 70-m strainer and the single-cell suspension was centrifuged for 5 minutes at 1500 rpm. The cell pellet was washed twice with 10 mL of cold phosphate-buffered saline (PBS) and the cell suspension was incubated with 20% rabbit sera for 40 minutes at 4°C. The cells were centrifuged and cell suspensions were incubated with a 1/100 dilution of rat anti-mouse CD31 Ab in PBS (PharMingen, San Diego, Calif) for 40 minutes at 4°C. The cells were washed three times in PBS and resuspended in a 1/400 dilution of Texas Redconjugated rabbit anti-rat immunoglobulin G in PBS (Vector Laboratories) for 40 minutes at 4°C. After additional washes, cells were resuspended and fixed in 0.5% freshly prepared paraformaldehyde. Cytospins (Shandon Lipshaw, Pittsburgh, Penn) were prepared by pelleting a 1/100 dilution of stained cells onto coated slides and were counter-stained with propidium iodide to highlight nuclei. Controls included unstained cells and incubation with secondary Ab alone. Cells were viewed with an Olympus BX-60 fluorescence microscope and photographed with a Montague spot camera. The proliferative activity in the endothelial cells of s.c. SCCVII tumors was determined by injecting BrdU intraperitoneally and costaining the dispersed tumor cells with anti-CD31 and anti-BrdU Ab. The cell isolation and CD31 staining of isolated cells were performed as described above. For BrdU staining, isolated cells were permeabilized and incubated with a mouse biotinylated anti-BrdU Ab. The Ab binding was visualized by streptavidin-peroxidase immunostaining with a kit method (Zymed, San Francisco, Calif).
Plasmid preparation
The expression plasmids pCMV-CAT, pCMV-human IL-12 (pCMV-hIL-12), and pCMV-murine IL-12 (pCMV-mIL-12) were isolated and purified from Escherichia coli as described previously. 5, 9 The purity of the plasmid preparations was determined by 1% agarose gel electrophoresis followed by SYBR Green (Molecular Probes, Eugene, Ore) staining, and the pDNA plasmid DNA (pDNA) concentration was measured by ultraviolet absorption at 260 nm. The percentage of supercoiled pDNA was in the range of 80 -95%. The optical density (OD) 260/280 ratios of these pDNA preparations were between 1.85 and 1.9.
Endotoxin levels of pDNA preparations were determined with the chromogenic Limulus amebocyte lysate assay (Chromogenic End-Point, LAL BioWhittaker, Walkersville, Md). Values were Ͻ20 endotoxin units/mL.
Preparation of lipid/plasmid complexes
Liposomes containing N-[ (1-(2,3-dioleyloxy) propyl)]-N-N-Ntrimethylammonium chloride (DOTMA) and cholesterol (CHOL) (Avanti Polar Lipids, Inc., Alabaster, Ala) were prepared at a 4:1 DOTMA:CHOL molar ratio. Briefly, lipids were mixed in chloroform and evaporated to a thin film in a 50-mL round-bottom flask by using a rotary evaporator. The film was hydrated in sterile water, probe-sonicated, centrifuged at 32,000 ϫ g for 30 minutes, and sterile-filtered to obtain small unilamellar vesicles. DOTMA:CHOL/plasmid complexes were formed in 10% lactose by controlled mixing of liposomes with DNA plasmid at a 3:1 (ϩ/Ϫ) charge ratio, yielding 0.3 mg/mL as a final plasmid concentration. The size of the transfection complexes was measured with a Brookhaven submicron particle sizer; an average diameter of 127 Ϯ 14 nm was observed. Agarose gel electrophoresis showed that all of the plasmid was complexed to the liposomes. The net surface charge of the transfection complexes was measured by Doppler electrophoretic light scattering with a Coulter Delsa 440 Zetasizer (Coulter, Miami, Fla). A potential of 45 Ϯ 8 mV showed that the complexes had a net positive charge.
In vivo gene transfer
The transfection complexes were administered into the tail vein of mice with s.c. primary tumors. The plasmid concentration in the formulation was fixed at 300 g/mL to yield a 90-g dose in 0.3-mL injection volume. For 15-, 45-, and 60-g doses, serial dilutions were made with 10% lactose to obtain plasmid concentrations of 50, 150, and 200 g/mL, respectively. Tumors were harvested at 15 minutes postadministration for plasmid uptake and from 8 hours to 10 days postadministration for expression. For efficacy studies, 15 g of pCMV-mIL-12 complexed with DOTMA:CHOL liposomes was administered once per week for 3 weeks by tail vein injection 7 days after tumor cell implantation. The tumor size was measured at designated times. For tolerability studies, transfection complexes were administered by tail vein injection into normal mice by the experimental protocol described for the tumor efficacy study. Blood, lung, liver, spleen, kidney, brain, and heart tissue were harvested 2 or 28 days after the last injection. Blood samples were analyzed for the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (IDEXX Veterinary Services, Dallas, Tex). The tissue organs were fixed in formaldehyde, sectioned, embedded on paraffin, and stained with hematoxylin/eosin for histopathological evaluation.
Assay for chloramphenicol acetyltransferase (CAT) and IL-12 expression in mouse tissue
Tumors and lungs were homogenized in 0.35 and 1 mL of TENT buffer, respectively. The tissue homogenate was centrifuged at 10,000 ϫ g for 15 minutes and supernatant was assayed for CAT or IL-12 with respective enzyme-linked immunosorbent assays (Boehringer Mannheim, Indianapolis, Ind).
Distribution of lipid/plasmid complexes in tumor
Psoralen-fluorecein-labeled plasmid 9 was used to examine plasmid distribution in tumors. Fluorescent-labeled pCMV-CAT was complexed with DOTMA:CHOL (4:1, mol/mol) at a 3:1 (ϩ/Ϫ) lipid/plasmid charge ratio and injected into tumorbearing mice via tail vein at a 90-g DNA dose. At 15 minutes postinjection, animals were anesthetized by intraperitoneal administration of a mixture of ketamine (42.8 mg/mL), xylazine (8.6 mg/mL), and acepromazine (1.4 mg/mL) at a dose of 0.5-0.7 mL/kg, and whole-body perfusion was performed with 1% bovine serum albumin/PBS solution to clear entrapped blood. Tumors were removed and embedded in OCT embedding medium. Colocalization of plasmid and endothelial cells was visualized with psoralen-fluorescein-labeled plasmid and immunostaining for CD31 endothelial cell marker with Texas Red-labeled Ab as described above.
Plasmid extraction from tissues and quantification
pDNA from lung or tumor tissue was digested by incubation with digestion buffer (100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 25 mM EDTA (pH 8.0), 0.5% sodium dodecyl sulfate, and 0.1 mg/mL proteinase K) at 50°C. The samples were extracted with an equal volume of Tris-buffered phenol (pH 8.0), followed by extraction with chloroform:isoamyl alcohol (24:1, vol/vol) and ethanol precipitation. The DNA precipitates were dissolved in TE buffer (10 mM Tris (pH 7.5), 1 mM EDTA), and DNA concentration was measured by ultraviolet absorption at 260 nm.
A polymerase chain reaction (PCR) assay with Taqman PCR (Perkin-Elmer, Foster City, Calif) was used to quantify the amount of pDNA associated with the tissue or cell extract. The primers used in the reaction were a forward primer (5Ј-GCCG-TAATATCCAGCTGAACG-3Ј) (Genosys Biotechnologies, The Woodlands, Tex), which primes in the cytomegalovirus (CMV) 5Ј untranslated region, and a reverse primer (5Ј-(FAM)G-CAAGTCGACCTATAATGCCG(TAMRA)-3Ј), which primes in the CAT-coding region. The probe sequence was 5Ј-CCAGC-CTCCGGACTCTAGAGGA-3Ј. The initial copy numbers of unknown samples were determined by using an Applied Biosystem 7700 sequence detector (ABI, Palo Alto, Calif) to compare them with a standard curve generated from purified pCMV-CAT of known initial copy numbers.
RESULTS
Characterization of s.c. tumor model
The primary s.c. tumor implants grew to 30 -80 mm 3 by 6 -7 days postimplantation and appeared to be highly vascularized upon histological examination by light microscopy. The relationship of tumor vascularity to tumor size was measured by i.v. administration of fluoresceinlabeled dextran. This probe will not extravasate out of the vasculature. This was verified by fluorescence microscopy of tumor sections, shown in Figure 1A . The fluorescent micrographs showed that fluorescence was restricted to the vasculature with no detectable extravasation into the interstitium. Tumors were harvested 15 minutes after i.v. administration and processed. The amount of fluorescein dextran associated with the tumor was measured as a function of tumor size. The results in Figure 1B show a linear relationship between dye accumulation and tumor size followed by an exponential relationship.
Tumor vascularization was characterized by immunohistochemical staining of the endothelium with anti-CD31 Ab. In Figure 2A , microscopy of tumor sections showed that the tumors were composed primarily of microcapillaries. Anti-CD31 immunostaining of dispersed tumor cell preparations showed that ϳ20% of the tumor cell population was endothelial cells (Fig 2B) . A fraction of the tumor endothelial cells (green) incorporated BrdU (red), thus identifying proliferating endothelial cells (Fig 2C) .
Systemic transfection of tumor endothelium
Cationic lipid-based transfection complexes administered i.v. distributed to multiple organs in non-tumor- bearing mice, with the majority accumulating in the lungs. In tumor-bearing transgenic mice, cationic lipidbased transfection complexes were shown to localize to tumor vasculature in the pancreas. 10 To assess this in the present mouse tumor system, transfection complexes were fluorescently labeled with plasmid that was covalently derivatized with psoralen-fluorecein, 7, 9 and tumors were processed for fluorescence microscopy. The results are shown in the fluorescent micrograph in Figure 3 . The tumor cells were labeled with propidium iodide, and the colocalization of both fluorophores yields a yellow fluorescence. No yellow fluorescence was observed outside of the vasculature. Another set of sections containing the fluorescent plasmid was counterstained with Texas Red-labeled anti-CD31 Ab, an endothelial cell marker. The results are shown in the higher magnification inset in Figure 3 . The colocalization of the two fluorophores also produced a yellow fluorescence, showing that the transfection complexes were associated with endothelial cells. The yellow fluorescence was observed on the endothelial cell surface and inside the cells.
The biodistribution and expression of the transfection complexes were assessed to determine the amount of plasmid accumulated by the tumor and whether the plasmid was biologically active. A 90-g plasmid dose of transfection complex was administered i.v. into s.c. tumor-bearing mice. Plasmid uptake was measured at 1 hour postadministration, and CAT expression was measured at 24 hours postadministration. Plasmid uptake and expression were analyzed for both tumor and lungs. The results are shown in Figure 4A . The left y axis represents CAT expression and the right y axis represents the amount of pDNA associated with the tissues. The results show pDNA accumulation in both the lungs and tumor. There is a 2-3 order of magnitude difference in uptake and a subsequent difference in expression as well. Further characterization showed that the amount of expression was dependent upon tumor size. This is illustrated in Figure 4B . The amount of CAT protein per gram of tumor was low in small tumors (Ͻ50 mm 3 ) and higher in large tumors (50 -200 mm 3 ). The duration of expression and the impact of repeat injections on gene expression were tested in tumorbearing mice and expression was compared between tumor and lungs. The results are shown in Figure 5 . CAT expression in both tumor and lung peaked between 8 and 18 hours postadministration. There was an ϳ3 order of magnitude difference in peak accumulation of CAT between lung and tumor tissue. The amount of CAT protein decreased over time, with 10% of the peak amount remaining in the lungs and 25% of peak of the peak amount remaining in the tumor at 10 days postadministration. Readministration of the same plasmid dose 3 days after the first injection restored the expression levels to the initial maximal value in tumor but had no effect on lung expression.
Expression of anticancer genes and inhibition of tumor growth
The performance of the DOTMA:CHOL formulation was evaluated for biological activity by expressing mIL-12 in the mouse s.c. tumor model. This cytokine has been shown to be an active immunostimulatory and antiangiogenic agent. 5, 11, 12 A plasmid encoding both subunits, p35 and p40 (each under a separate CMV promoter), was formulated with the cationic lipid system at a 3:1 (ϩ/Ϫ) charge ratio. Expression was compared among lungs, tumor, and blood as a function of plasmid dose. hIL-12 was used to assay expression to avoid potential background contamination due to endogenous mIL-12. The results are shown in Figure 6 . The left-hand y axis represents IL-12 for the tissues and the right-hand y axis represent IL-12 in the blood. The results showed that IL-12 was secreted into the blood and also was The effect of mIL-12 protein levels on primary tumor growth rate was determined. The 15-g dose was selected to minimize the amount of IL-12 in the blood. The dosing schedule consisted of three administrations 7 days apart. Dosing was initiated 7 days after tumor implantation. The tumors ranged from 30 to 50 mm 3 . A CAT expression plasmid was used for the irrelevant plasmid control. The results are shown in Figure 7 . The tumors in mice treated with the IL-12 expression plasmid grew more slowly than the untreated control or the irrelevant plasmid control. The inhibition of tumor growth was statistically significant compared with irrelevant plasmid at 10 days (36%, P Ͻ .05) and 15 days (35%, P Ͻ .05), thus demonstrating a specific gene inhibitory effect on tumor growth.
Tolerability of lipid/plasmid complexes
The tolerability of transfection complexes after tail vein injection was evaluated in normal male and female mice with the same plasmid dose and dosing schedule as in the efficacy study. Animals were sacrificed at 2 or 28 days after the third injection. Blood, lung, liver, spleen, kidney, brain, and heart tissue were harvested for histological pathology analysis. Blood samples were analyzed for standard blood chemistries, including alkaline phosphatase, liver enzymes ALT and AST, albumin, total protein, globulin, blood-urea-nitrogen, creatine, CHOL, glucose, calcium, phosphorus, potassium, and sodium. The liver enzymes ALT and AST were elevated compared with lactose and untreated controls at 2 days postadministration. The results are summarized in Table  1 . The magnitude of the increase is difficult to assess for the IL-12 plasmid due to the high degree of variability for both enzyme levels. Two of six mice had AST and ALT levels that were 20-fold higher than controls, with the others ranging from 1-to 3-fold higher than controls. One of seven mice had ALT and AST levels that were 20-fold higher than controls, with the other six mice showing levels ranging from 1-to 5-fold higher than controls. At 28 days after the last injection, both enzyme levels for IL-12 and irrelevant plasmid returned to baseline. Gross tissue examination did not show obvious pathology in either the IL-12-or irrelevant plasmid- 
DISCUSSION
This report characterizes systemic gene transfer of a cationic lipid-based transfection complex to tumor-bearing mice. Moreover, the application of this delivery technology for expression of an anticancer cytokine resulted in inhibition of tumor growth. The primary squamous cell tumors used for gene transfer studies are a very aggressive tumor line with regard to growth rate. Consequently, they were highly vascularized as determined by CD31 immunostaining and FITC-dextran labeling. The single-cell dispersion of the tumors yielded an 18% total cell recovery based on genomic DNA. Of the cells recovered, ϳ20% were endothelial cells. BrdU staining showed that some of the endothelial cells were in the process of undergoing or had undergone cell division. The observed linear relationship between tumor size and FITC-dextran uptake in s.c. tumors is consistent with the hypothesis that tumor vascularity is a crucial determinant in the growth of solid tumors. 13, 14 In the early phase of growth, a more linear relationship of surface to volume is observed. Once the tumors reached a critical size, this relationship shifted to an exponential function. The fluorescent dextran uptake data in Figure  1 illustrate this point. The fluorescent dextran results are consistent with the expression results as a function of tumor size (shown in Fig 4B) . These results showed that as the tumor size increased, the amount of reporter gene increased on a per gram basis. The fluorescent micrographs from Figure 3 showed that the uptake of the fluorescent-labeled transfection complexes was restricted to the tumor vasculature. Hence, increased tumor cell growth resulted in increased vascularity of the tumor, thus increasing the number of endothelial cells available for transfection.
From the observations that the endothelium was the predominant if not the sole cell type being transfected, and that a percentage of the administered dose was transfecting the tumor as well as the lungs, the next question that arose was whether the transgene expression level was sufficient to elicit a biological response let alone yield a therapeutic effect. Expression of IL-12 was selected to address this question. Not only does it play a role in T-cell and natural killer cell activation and proliferation, but it has also been reported to have antiangiogenic activity. 11, 12, [15] [16] [17] An added bonus was that an enzyme-linked immunosorbent assay was available that had a sensitivity of 10 pg/mL, allowing the amount of transgene product to be assayed at a therapeutically relevant plasmid dose.
Treatment conditions were selected that would maximize the probability of success. These included the effect of tumor size on expression to determine when to begin treatment. The CAT expression results showed that the larger tumors with volumes of Ն50 mm 3 yielded higher expression levels than smaller tumors. At 7 days postimplantation, the tumors were palpable (ϳ30 mm 3 ) and treatment was initiated.
Another concern was the plasmid dose. The 15-g plasmid dose was selected based on the plasmid dose response that showed that this dose yielded higher levels of IL-12 in the lungs and tumor compared with blood, thus minimizing potential side effects due to elevated IL-12 blood levels. 18 -20 The third component was the dosing schedule. Repeat injection experiments showed an increase in the duration of tumor expression but had no effect on lung expression. The 7-day lag period between injections was selected based on the results obtained from the repeat injection study. This 7-day period would be inside the refractory period for the lungs and outside the refractory period for the tumor. Hence, the second and third administrations would preferentially transfect the tumor, reducing expression in the lungs and subsequently reducing the IL-12 blood levels, and thus minimizing any potential side effects.
All of the optimized conditions were used to test the biological activity of the transfection complexes. A CAT reporter plasmid was used as an irrelevant plasmid control. It has been shown that these transfection complexes can cause release of secondary cytokine that can impact tumor growth. The tumor growth inhibition studies showed that the degree of inhibition of the tumor growth rate for the IL-12-treated mice was consistently greater than that obtained with the irrelevant plasmid, and the extent of inhibition was statistically significant.
Even though a specific gene effect was observed, the degree of nonspecific inhibition compared with the untreated control was also significant and was a concern with regard to tolerability. The small-scale tolerability study was designed to investigate this aspect. Blood chemistry showed elevated liver enzymes for both the IL-12 and irrelevant plasmid, with the IL-12 plasmid levels being slightly higher than those for the irrelevant plasmid. The highest levels were only 2-fold above the normal range. Histopathology showed an occasional micronecrotic lesion in the liver. The recovery phase of the study showed that blood chemistry returned to normal. Hence, these results showed that the plasmid dose and dosing schedule impacted the liver, but with minimal effects.
For this to become a viable systemically administered therapy, several aspects need to be improved. First, lung uptake needs to be reduced and tumor uptake needs to be increased. This will not only reduce the effective dose but also minimize any potential deleterious side effects, depending upon the transgene. Second, the transfection efficiency needs to be increased and/or expression of transgenes with increased potency needs to be optimized to completely suppress tumor growth rather than simply decrease the growth rate. Examples of technology that can overcome these limitations are reduction of nonspecific cell interactions with masking technologies, such as incorporating polyethylene glycol; transfection complex targeting with ligands to yield selective uptake to tumor vasculature; coformulation of agents to facilitate endocytic vacuole escape of the delivered gene, such as pH-dependent lytic peptides 21, 22 or proton-absorbing polymers; 23 and increased nuclear uptake of the plasmid either by incorporating nuclear localization agents 24 or by simply including DNA sequences that endogenous nuclear localization proteins can recognize. 25 There are several alternative types of genes that can be expressed with increased potency. These can be other antiangiogenic factors, such as angiostatin, 26 endostatin, 27 proteolyzed antithrombin 3, 28 pigment epithelium-derived factor, 29 soluble Flk1, 30 or humanized Abs raised against growth factor receptors, such as epidermal growth factor receptor, 31 vascular endothelial growth factor, 32 or vascular endothelial growth factor receptor. 33 These genes can be administered by themselves or in combination and can be expressed on the same plasmid. Based on the present experimental observations, the above-mentioned improvements in the performance of the existing technology along with expression of genes that directly impact the tumor as well as the endothelium should make the goal of complete tumor elimination achievable by systemically administered plasmid-based gene therapies.
